AZN: H1 2018 Results
AstraZeneca PLC 26 July 2018 07:00 BST H1 2018 Results Strong performances from new medicines and Emerging Markets underpin the return to growth in 2018 Over the first half, the strong sales growth from new medicines (+75%, +69% at CER1) and the continued strength of the Emerging Markets business (+14%, +10% at CER) were offset by the impact from the loss of Crestor exclusivity in Europe and Japan. In line with expectations, an improved performance is anticipated in the second half, notably Product Sales, where guidance is reiterated for a low single-digit percentage increase